Structured around the development of drug therapies to treat cancer, OncoSpherix is a biotechnology company developing small-molecule drug therapies. It is well known that cancerous tumors have spots where the cancer cells receive less blood - effectively depriving the cells of oxygen and making them weaker. OncoSpherix is focused on attacking these regions specifically. Anchored in innovative work undertaken at Emory University, Georgia State University and Scripps Research Institute, OncoSherix' drugs target H1FI -- a gene expressed in hypoxic (low-oxygen) cancer cells, and one that plays a key role in the cellsâ continued survival and spread. In pre-clinical studies, the companyâs most promising drug candidates indicate strong results against multiple kinds of advanced cancers. With OncoSpherix potentially being used in combination with other cancer treatments that prevent growth and spread of cancer, this could be helping to provide an effective and successful treatment plan for cancer patient
